|
Gene: PLA2G7 |
Gene summary for PLA2G7 |
Gene summary. |
Gene information | Species | Human | Gene symbol | PLA2G7 | Gene ID | 7941 |
Gene name | phospholipase A2 group VII | |
Gene Alias | LDL-PLA2 | |
Cytomap | 6p12.3 | |
Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | Q13093 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
7941 | PLA2G7 | HCC2 | Human | Liver | HCC | 5.82e-05 | 6.14e-01 | 0.5341 |
7941 | PLA2G7 | HCC5 | Human | Liver | HCC | 2.57e-02 | 3.37e-01 | 0.4932 |
7941 | PLA2G7 | Pt13.a | Human | Liver | HCC | 1.41e-07 | 3.20e-01 | 0.021 |
7941 | PLA2G7 | Pt13.c | Human | Liver | HCC | 2.85e-03 | 2.54e-01 | 0.0076 |
7941 | PLA2G7 | Pt14.d | Human | Liver | HCC | 3.05e-02 | 1.54e-01 | 0.0143 |
7941 | PLA2G7 | S014 | Human | Liver | HCC | 2.66e-13 | 5.20e-01 | 0.2254 |
7941 | PLA2G7 | S015 | Human | Liver | HCC | 4.55e-16 | 8.53e-01 | 0.2375 |
7941 | PLA2G7 | S016 | Human | Liver | HCC | 1.18e-15 | 8.02e-01 | 0.2243 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004424222 | Liver | HCC | cellular lipid catabolic process | 134/7958 | 214/18723 | 2.07e-09 | 5.79e-08 | 134 |
GO:00066444 | Liver | HCC | phospholipid metabolic process | 214/7958 | 383/18723 | 7.25e-08 | 1.48e-06 | 214 |
GO:003444021 | Liver | HCC | lipid oxidation | 73/7958 | 108/18723 | 1.17e-07 | 2.25e-06 | 73 |
GO:004648611 | Liver | HCC | glycerolipid metabolic process | 215/7958 | 392/18723 | 4.54e-07 | 7.49e-06 | 215 |
GO:003025821 | Liver | HCC | lipid modification | 123/7958 | 212/18723 | 3.50e-06 | 4.58e-05 | 123 |
GO:001604221 | Liver | HCC | lipid catabolic process | 175/7958 | 320/18723 | 6.50e-06 | 7.88e-05 | 175 |
GO:00066504 | Liver | HCC | glycerophospholipid metabolic process | 168/7958 | 306/18723 | 7.27e-06 | 8.62e-05 | 168 |
GO:00464342 | Liver | HCC | organophosphate catabolic process | 89/7958 | 155/18723 | 1.24e-04 | 1.03e-03 | 89 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PLA2G7 | SNV | Missense_Mutation | c.1314G>T | p.Glu438Asp | p.E438D | Q13093 | protein_coding | tolerated_low_confidence(0.23) | benign(0) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD | |
PLA2G7 | SNV | Missense_Mutation | c.331N>A | p.Leu111Ile | p.L111I | Q13093 | protein_coding | tolerated(0.09) | possibly_damaging(0.777) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
PLA2G7 | SNV | Missense_Mutation | novel | c.1120G>T | p.Asp374Tyr | p.D374Y | Q13093 | protein_coding | deleterious(0.01) | possibly_damaging(0.463) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
PLA2G7 | SNV | Missense_Mutation | rs201567357 | c.653G>A | p.Arg218Gln | p.R218Q | Q13093 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PLA2G7 | SNV | Missense_Mutation | c.155G>A | p.Gly52Asp | p.G52D | Q13093 | protein_coding | tolerated(0.07) | benign(0.058) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PLA2G7 | SNV | Missense_Mutation | rs368035023 | c.99N>A | p.Met33Ile | p.M33I | Q13093 | protein_coding | tolerated(1) | benign(0) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PLA2G7 | SNV | Missense_Mutation | novel | c.1025N>C | p.Lys342Thr | p.K342T | Q13093 | protein_coding | deleterious(0) | probably_damaging(0.931) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
PLA2G7 | SNV | Missense_Mutation | c.1314N>T | p.Glu438Asp | p.E438D | Q13093 | protein_coding | tolerated_low_confidence(0.23) | benign(0) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response | |
PLA2G7 | insertion | Frame_Shift_Ins | novel | c.789_790insG | p.Arg264GlufsTer21 | p.R264Efs*21 | Q13093 | protein_coding | TCGA-D1-A0ZZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | paclitaxel | SD | ||
PLA2G7 | insertion | Frame_Shift_Ins | novel | c.410_411insC | p.Leu138SerfsTer5 | p.L138Sfs*5 | Q13093 | protein_coding | TCGA-EO-A3AU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7941 | PLA2G7 | DRUGGABLE GENOME, ENZYME | inhibitor | 178103948 | RILAPLADIB | |
7941 | PLA2G7 | DRUGGABLE GENOME, ENZYME | inhibitor | CHEMBL2104981 | RILAPLADIB | |
7941 | PLA2G7 | DRUGGABLE GENOME, ENZYME | Rilapladib | RILAPLADIB | ||
7941 | PLA2G7 | DRUGGABLE GENOME, ENZYME | DARAPLADIB | DARAPLADIB | ||
7941 | PLA2G7 | DRUGGABLE GENOME, ENZYME | inhibitor | 354702268 | ||
7941 | PLA2G7 | DRUGGABLE GENOME, ENZYME | Indolizine derivative 1 | |||
7941 | PLA2G7 | DRUGGABLE GENOME, ENZYME | inhibitor | 354702269 | ||
7941 | PLA2G7 | DRUGGABLE GENOME, ENZYME | inhibitor | 375973250 | ||
7941 | PLA2G7 | DRUGGABLE GENOME, ENZYME | ERYTHROPOIETIN | EPOETIN BETA | 16421163 | |
7941 | PLA2G7 | DRUGGABLE GENOME, ENZYME | GSK2647544 |
Page: 1 2 |